secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001847903-25-000133
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa Q2 net loss $50.3M; cash $404.1M; ORX750 Phase 2a data on track for 2025
--------------------------------------------------------------------------------

- Net loss of $50.3M for Q2 2025, up from $43.8M in Q2 2024; R&D expenses rose to $42.7M.
- Cash, cash equivalents and investments totaled $404.1M as of June 30, 2025, expected to fund into mid-2027.
- ORX750 Phase 2a CRYSTAL-1 study ongoing; data in NT1, NT2, and idiopathic hypersomnia expected in 2025.
- ORX142 Phase 1 first-in-human trial initiated; data in sleep-deprived healthy volunteers expected in 2025.
- ORX489 in IND-enabling studies for neuropsychiatric disorders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790325000133/0001847903-25-000133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790325000133/cnta-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001847903-25-000133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer